Tom is the CEO of Surescripts. He joined Surescripts in order to be at the forefront of what’s next in healthcare and a positive impact on our nation’s healthcare system. He remains amazed by the changes he’s seen over the course of more than 30 years working in healthcare technology, including roles as Chief Executive Officer of Foundation Radiology Group and Misys Healthcare Systems.
The CEO of Surescripts believes we are living in an unpredictable world coupled with an explosion of innovation that aims to solve challenges like the cost of medications, administrative inefficiency and gaps in patient information.
The CEO of Surescripts shares his predictions for the health IT segment that include policy and technology projections.
FASENRA® (benralizumab) injection, for subcutaneous use, 30 mg is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). FASENRA provides a treatment option for HCPs to consider when managing this challenging disease.
Looking forward to 2020, the most important new voice on this topic will be the consumer. Will there be massive consumer-directed outflows of data from healthcare incumbents to new entrants? Data security and privacy will be debated vigorously by all stakeholders. And, without question, trust will take center stage.